Alain Baron, President & CEO, Director, Elcelyx
Alain Baron founded Elcelyx Therapeutics in 2009 and was named President and CEO in 2010. Prior to Elcelyx, Dr. Baron was an Entrepreneur-in-Residence and a member of the Life Science Team at Morgenthaler Ventures, a position he has held since 2008.
Prior to joining Morgenthaler, he was Senior Vice President of Research at Amylin Pharmaceuticals where he served in senior roles in R&D since 1999. Previously, Dr. Baron worked at Indiana University School of Medicine in Indianapolis, where he served as Professor of Medicine and Director, Division of Endocrinology and Metabolism. He has also held faculty positions in the Division of endocrinology and Metabolism at University of California, San Diego. He is the recipient of several prestigious awards for his research in diabetes and vascular disease, including the 1996 Outstanding Clinical Investigator Award from the American Federation for Medical Research. He is an elected member of the American Society for Clinical Investigation and the Association of American Professors. He is also a past National Institutes of Health MERIT award recipient, co-editor of the Ellenberg & Rifkin Textbook of Diabetes, and has authored over 100 original publications and is an inventor on more than 30 patents.
Dr Baron graduated from McGill University, Canada (B.Sc. in Biology with honors) and the Medical College of Georgia Augusta (MD). Postdoctoral studies were completed at the University of California, San Diego.
Miranda Biven, Partner, Wilson Sonsini Goodrich & Rosati
Miranda Biven is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Her practice focuses on representing clients in transactions primarily in the life sciences industry. Miranda has significant experience in negotiating and drafting product licensing and collaboration arrangements, research and development agreements, agreements with academic institutions, manufacturing and supply agreements, and clinical trial arrangements. She also counsels clients on a variety of legal and business issues related to technology or intellectual property transactions. Miranda works with both early-stage and public companies located in the United States and internationally.
Prior to joining Wilson Sonsini Goodrich & Rosati in 2005, Miranda worked in the New York office of Kirkland & Ellis and the Sydney, Australia, office of Baker & McKenzie. Miranda also has an interest in intellectual property policy issues and worked as a senior legal officer at the Australian Law Reform Commission on its inquiry "Gene Patenting and Human Health."
•LL.M., Harvard Law School
•B.A.(First Class Honours), University of Sydney
•LL.B.(First Class Honours), University of Sydney
•State Bar of California
•State Bar of New York
•State Bar of New South Wales (Australia)
Richard Brudnick, Vice President of Business Development, Biogen-Idec
Richard joined Biogen Idec in 2001 in the business development group and has led or played a major role in numerous major transactions including licenses, acquisitions and collaborations which now feature prominently in Biogen Idec's pipeline. These include Phase 3 and registration stage programs such as BG12 and daclizumab for MS, dexpramipexole for ALS, and long-acting Factor VIII and IX therapies for hemophilia. Others represent potentially paradigm changing future therapeutics such as a portfolio of antibodies against various targets believed to be important for proteinopathies associated with cognitive disease and an anti-sense therapy for SMA. Richard also conceived and led Biogen Idec's recent biosimilars joint venture with Samsung. Prior to Biogen Idec, Richard was CEO of a regional pharmaceutical distribution business which he grew to over $200 million in annual sales and then led the sale of the company to a strategic buyer. Before entering the pharmaceutical and biotech industry, he was an entrepreneur who co-founded two companies and began his career as a strategy consultant at Bain & Company. Richard earned his undergraduate and graduate degrees at the Massachusetts Institute of Technology.
Tom Bumol, Site Head at AME, Eli Lilly and Company
Thomas F. Bumol, Ph.D., is currently the Vice President of the Biotechnology Discovery and Autoimmunity Research component at Lilly Research Laboratories, Indianapolis, Indiana and the President/Site Head of Lilly's Biotechnology Center of San Diego. Since February of 2004, Dr. Bumol's responsibilities also include Applied Molecular Evolution, a wholly owned subsidiary of Eli Lilly and Company based in San Diego, California. He is also the chairperson of the company's Bioproduct Strategy Group and a member of the company's Portfolio Management Team.
A native of Detroit, Michigan, he received his B.S. degree in microbiology with distinction from the University of Michigan in 1975. He subsequently completed his Ph.D. in microbiology from the University of Minnesota in 1980. Dr. Bumol was the recipient of a Damon Runyon-Walter Winchell Cancer Research Fellowship for his postdoctoral studies in the Department of Molecular Immunology at Scripps Clinic and Research Foundation in La Jolla, California from 1980-1982. He joined Lilly Research Laboratories as a Senior Immunologist in 1982 where he has remained for his career over the past twenty-eight years.
He serves on the Scientific Advisory Board for the Keystone Symposia and the University of Michigan Tech Transfer National Advisory Board. He is also serving on the internal scientific advisory board for the Lilly BioVentures Group and the Commercial Advisory Board for the Indiana University-Purdue University Center in Regenerative Biology. He is the former Chair of the Board of Directors of the Timmy Foundation, a non-profit organization directing health care resources to children and families in third world countries.
Dan Burgess, President & CEO, Rempex Pharmaceuticals
Mr. Burgess has more than 20 years of executive level experience in the biotechnology and pharmaceutical industries. Prior to helping found Rempex in 2011, Mr. Burgess was President and CEO of Mpex Pharmaceuticals, which he joined in 2007. During his tenure as CEO, Mpex advanced its lead product Aeroquin from Phase 1 into Phase 3 clinical trials, raised substantial venture capital funding and ultimately achieved a successful exit in 2011 with its acquisition by Aptalis. Before joining Mpex, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Hollis-Eden Pharmaceuticals, Inc., a publicly traded biotechnology company focused on biodefense, infectious disease and immune system disorders. Previously, he spent ten years at Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited), a specialty pharmaceutical firm, where he held a variety of executive level positions with responsibility for overall finance for the company as well as a number of different operating units. Mr. Burgess received his BA in Economics from Stanford University and an MBA from Harvard Business School. Mr. Burgess is a member of the Board of Directors of Santarus, Inc.
Iain Dukes, Vice President, External Research and Development, Amgen
Dr. Dukes has been with Amgen since August 2010 as Vice President of External Research and Development. He has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, consultant to numerous biotech and venture capital organizations.
In his current role, Iain leads the External R&D department in identifying, assessing and transacting scientific external licensing opportunities, as well as potential opportunities for academic collaborations and platform technologies.
Previously, Iain was President and CEO of Essentialis Therapeutics, a small start-up company, and before that he served as Vice President, Scientific and Technology Licensing at GlaxoSmithKline, where he built a leading licensing organization. At an earlier point, he was the Head of the Ion Channel Drug Discovery Group, and later Head of Exploratory Development in
Metabolic and Urogenital Diseases at GlaxoWellcome.
Iain pursued initial research training at the University of Leeds, UK, and received
his D.Phil. degree from the University of Oxford where he also received a B.A. in
Jurisprudence. He was a post-doctoral fellow in the Department of Physiology at the
University of Pennsylvania, while simultaneously completing training at Gray's Inn, UK in
anticipation of being called to the Bar.
Lewis Geffen, Co-Chair, VC and Emerging Companies Practice, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo
Lewis is Co-chair of the firm's Venture Capital & Emerging Companies Practice, focusing primarily in the areas of venture capital, mergers and acquisitions, corporate law, intellectual property, and securities law.
He regularly represents technology-based companies, principally in the areas of biotechnology, medical devices, medtech, diagnostics and healthcare. His clients range in size from start-up ventures to large public companies. He routinely counsels these clients on their growth and development, advises their management and boards of directors, and assists them with a wide range of domestic and international transactions, including venture capital and other private financings, technology licensing, mergers and acquisitions, strategic partnerships, and public offerings.
Lewis also regularly represents venture capital firms in both fundraising and portfolio investment activities and underwriters in public offerings and private placements of equity and debt securities.
George S. Golumbeski, Senior Vice President Business Development, Celgene Corporation
In a career spanning nearly 20 years, George has held senior positions in R&D and Business Development. In his most recent two positions, he has led business development functions at leading oncology companies. He has a strong record of closing significant in-licensing and M&A transactions.
George is currently Senior Vice President of Business Development for Celgene Corporation, where he is responsible for the full array of business development activities (identification & evaluation of opportunities, structuring & negotiating transactions, in-licensing, M&A, outlicensing, and alliance management). At Celgene, these activities are focused within the therapeutic areas of oncology and inflammation.
Prior to Celgene, George served as Vice President of Business Development, Licensing and Strategy for Novartis-Oncology. During his tenure at Novartis, George's group closed a significant number of collaboration agreements which bolstered the development pipeline. Earlier in his career, George held senior positions at Elan Pharmaceuticals and at Schwarz Pharma, where he led the effort to in-license rotigotine and lacosamide (both now approved agents). In most of his positions, George has served on the R&D and/or Corporate Leadership Teams.
George received a BA in Biology from the University of Virginia, a PhD in Genetics from the University of Wisconsin-Madison. He has spoken frequently at industry conferences and leading business schools on a variety of topics related to the collaborations within the biopharmaceutical industry.
Corey Goodman, Partner, venBio LLC
Corey Goodman, PhD is a co-Founder and Managing Partner of venBio. Dr. Goodman is a renowned scientist, entrepreneur, educator, CEO, and corporate executive. He was formerly President of Pfizer Inc.'s Biotherapeutics and Bioinnovation Center, and a member of Pfizer's Executive Leadership Team. Dr. Goodman was a co-founder of Exelixis Inc., Renovis Inc., Second Genome Inc., and Ossianix Inc., and CEO of Renovis until its acquisition by Evotec. He is a former professor at Stanford University and UC Berkeley, co-founder of Berkeley's Wills Neuroscience Institute, an Investigator with the Howard Hughes Medical Institute, and currently an Adjunct Professor at UC San Francisco. Dr. Goodman is an elected member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. His honors include, amongst others, the Alan T. Waterman Award from the National Science Board, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Trinity College Dublin Dawson Prize in Genetics. He is on the Board of the California Council on Science and Technology, the Pacific Institute, and former chair of the National Academy of Sciences' Board on Life Sciences. He is an advisor to several university innovation centers and disease foundations. He is Chairman of the Board of several companies, including Solstice Biologics, Labrys Biologics, Oligasis, Ossianix, and Second Genome, and a member of the Board of several others, including NeuroTherapeutics Pharma Inc. and Mirna Therapeutics Inc. Dr. Goodman is located in venBio's San Francisco office.
Kurt Graves, Chairman & CEO, Intarcia Therapeutics, Inc.
Mr. Graves is a global industry leader with more than twenty years of US and global general management experience in top-tier US and European based pharmaceutical and biotech companies. He has successfully built and managed several of the largest multi-billion dollar franchises in the industry and developed and launched more than 10 blockbuster brands in a broad range of general medicine, specialty and orphan disease areas. In addition to driving dynamic top and bottom-line growth in large global pharmaceutical companies, Mr. Graves also played a key leadership role in building two highly successful early stage companies; at Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. Most recently Mr. Graves served as the Executive Chairman of Intarcia Therapeutics. Prior to that Mr. Graves was EVP, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals from 2007 through the end of 2009. Prior to his tenure at Vertex, he spent nearly ten years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business & Chief Marketing Officer for the Pharmaceuticals division. Prior to his tenure at Novartis, Mr. Graves held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. Mr. Graves serves as Chairman of the Board at Intarcia and Radius therapeutics and as a Director at Springleaf Therapeutics and Pulmatrix Pharmaceuticals. Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, Wharton School of Management and University of Michigan.
Richard Heyman, President and CEO, Aragon Pharmaceuticals
Rich Heyman has 20 years of drug discovery experience in the biotech sector and most recently co-founded Aragon Pharmaceuticals in 2009 with Charles Sawyers from MSKCC, Mike Jung from UCLA and Rick Klausner from The Column Group, where he is President and CEO. Aragon focuses on the discovery and development of small molecule therapeutics to treat hormone dependent cancers. Previously, he co-founded X-Ceptor Therapeutics with Ron Evans (Salk Institute) and David Mangelsdorf (UTSW) and was Chief Scientific Officer. X-Ceptor developed compounds targeting orphan nuclear receptors for the treatment of metabolic diseases. Prior to X-Ceptor, Rich was Vice President of Research at Ligand Pharmaceuticals, where, he was a co-discoverer of two compounds, Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer. He received his B.S. in Chemistry, a Ph.D. in Pharmacology and was an NIH Postdoctoral Fellow and Staff Scientist working with Dr. Ron Evans at The Salk Institute.
David Kabakoff, Executive Partner, Sofinnova
David Kabakoff joined Sofinnova Ventures as an Executive Partner in 2007. David has 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields. He currently serves as Chairman of Trius Therapeutics, Chairman of Cebix Inc., and Chairman of Amplimmune, Inc. He is also a Director of InterMune, Inc., and Allylix, Inc. Dr. Kabakoff also serves as a Board Observer at Histogenics.
David co-founded Salmedix, Inc., a developer of cancer drug treatments, and served as the company's Chairman and Chief Executive Officer. In June 2005, David negotiated the acquisition of Salmedix by Cephalon, Inc. David also held the positions of Executive Vice President of Dura and President and Chief Executive Officer of Spiros Development Corp. while at Dura Pharmaceuticals, a specialty respiratory pharmaceutical and pulmonary drug delivery company. Earlier, David was also employed as Chief Executive Officer of Corvas International and held senior executive positions with Hybritech, Inc.
David received his Ph.D. from Yale University and his B.A. from Case Western Reserve University.
Adam Keeney, VP, Head of Transactions, Johnson & Johnson West Coast Innovation Centers
Adam heads the Transactions group within the Johnson & Jonson Innovation Center - a novel approach to accelerate early innovation and enhance opportunities for collaboration and investment across J&J's healthcare businesses. Located in Menlo Park, CA, the West Coast Innovation Center will serve as a regional hub focused on identifying early-stage innovations, establishing novel collaborations and enhancing speed of development. The innovation center houses science and technology experts as well as local deal-making capabilities, with flexibility to adapt deal structures to match early-stage opportunities (defined as before clinical proof of concept).
Adam has a PhD in Neuropharmacology from the University of Nottingham, UK. After his post doc studies, Adam joined H. Lundbeck A/S in Copenhagen (Denmark) working in the Neuroscience Drug Discovery group. While at Lundbeck, Adam moved to lead the Scientific Licensing team within Business Development. Adam joined the Johnson & Johnson Pharmaceutical Business Development group in 2004 and has held numerous roles with increasing responsibility, most recently as Vice President and Head of Cardiovascular & Metabolism Licensing.
Rick Lindberg, Executive Director and Site Head, Centers for Therapeutic Innovation, California, Pfizer Inc.
As the Head of CTI- California Rick is responsible for research sites in San Francisco and San Diego that will work with universities and scientific institutions in new, creative, and innovative ways. Currently he is working with the University of California, San Francisco, Sanford-Burnham Medical Research Institute, and the University of California, San Diego. He is leading the effort to identify new collaborative programs and will manage a portfolio designed to quickly translate basic science into Phase 1 clinical trials.
Before joining Pfizer in 2011, Rick was at Amgen, most recently as Executive Director in Discovery Research, directing efforts in metabolic disorders, including diabetes and dyslipidemia. He also served as a member of the Scientific Advisory Board for Amgen Ventures and as a member of the General Medicine Therapeutic Area Strategic Committee. Before working in metabolic disorders, Rick made significant contributions to the tyrosine kinase and signal transduction fields at Amgen, and prior to that at the Salk Institute of Biology.
Rick holds a BS in Zoology and a MS in Physiology from Washington State University and a PhD in Biology from University of California, San Diego.
Brian McVeigh, Vice President, WWBD Transactions and Investment Management, GlaxoSmithKline Pharmaceuticals
Brian McVeigh is the Vice President of Worldwide Business Development Transactions and Investment Management at GlaxoSmithKline (GSK). In this capacity he leads a global team of Business Development professionals responsible for GSK's business development deals including in-licenses, out-licenses, research collaborations, co-development and co-promotion arrangements, joint ventures, product acquisitions, newco startups, equity investments, and M&A deals. He also has responsibility for managing GSK's portfolio of equity investments in R&D collaboration partners and GSK's portfolio of LP investments in venture capital funds.
Brian has held a number of positions of increasing responsibility within the R&D Finance, Marketing, Corporate, and Worldwide Business Development organizations throughout his 20 year career with GSK. Brian has extensive business development experience having successfully led a broad range of business development transactions including the acquisitions of Domantis, Praecis, Sirtris, and Genelabs, and the in-licensing of ambrisentan (Volibris®). Brian is a member of GSK's Business Development Executive Committee, Transactions Leadership Team, and the Technology Investment Board. He serves on the Board of Directors of the SB1 Federal Credit Union, the Strategic Advisory Board of the Longwood Founders Fund, and the LP Advisory Committee's of the Index Ventures Life VI fund, Hatteras Venture Partners III Fund, and Hatteras Venture Partners IV Fund. In 2012 he was named one of Philadelphia's Top 40 Business People Under the Age of 40.
Brian holds Bachelor of Science degrees in Accounting and Finance from LaSalle University, an MBA with a Concentration in Finance from Villanova University, a Post MBA Certificate in Pharmaceutical Marketing from Saint Joseph's University, and a CPD from the Wharton Business School. He is a member of the Licensing Executives Society and is a Certified Public Accountant, Certified Management Accountant, and a Certified Licensing Professional.
Ronald C. Newbold, Vice President - Strategic Research Partnerships, External R&D Innovation, Worldwide Research & Development, Pfizer, Inc.
Dr. Ron Newbold is Head, Strategic Research Partnerships (SRP) within External R&D Innovation (ERDI). Ron and his group identify new and support established Worldwide Research & Development (WRD) alliances with numerous universities and biotechnology companies across the globe. The mission of the External R&D organization is to strengthen Pfizer's access to cutting edge science at institutions in the US and Europe in alignment with the needs of Pfizer's Research Units. Ron also has responsibility for the activities of The Pfizer Incubator and for Pfizer's global scouting activities. He supports Pfizer's investments into early-stage technologies and enabling scientific opportunities in direct alignment with Pfizer's research interests.
Ron brings to Pfizer significant experience in external partnering in the Life Sciences field from his previous activities in large Pharma as well as entrepreneurial start-up experience with 3 early-stage biotech companies. After receiving his PhD in Organic Chemistry from the University of Rochester and a postdoctoral fellowship with Nobel Laureate E.J. Corey at Harvard University, he joined Merck where he founded and led their Strategic Research Initiatives licensing team from 1996-2004. Ron earned an MBA from Columbia Business School in 2003.
Following 14 years with Merck, Ron led business development for Sentigen Biosciences (founded by 2004 Nobel Laureate Richard Axel of Columbia University); Celldex Therapeutics (a spin-out from Medarex); and Auspex Pharmaceuticals, where he served as Chief Business Officer, prior to joining Pfizer in 2010.
Terence G. Porter, Vice President, Search & Evaluation, Global Business Development, Takeda
Terry Porter joined Takeda's Global Business Development & Licensing group in December 2011 where he heads the Search and Evaluation (S&E) team responsible for identifying and evaluating in-licensing opportunities across Takeda's four therapeutic areas (Cardiovascular-Metabolic, CNS, Inflammation-Respiratory, General Medicine) outside of Oncology and Vaccines.
Terry has over 25 years experience in the pharmaceutical and biotechnology industry; prior to Takeda, he was Managing Director at Aqua Partners, which provided strategic advisory services to life science companies and investors. Before that he had a long and successful career at GlaxoSmithKline (GSK), first as a research investigator, then as an integral member of GSK's global business development group where he held various leadership positions responsible, in partnership with key R&D stakeholder groups, for delivering upon GSK's global external science and technology strategy.
Starting out in Biotech at Seragen Inc., Terry has a broad knowledge across multiple aspects of business development including compound and technology assessment and licensing transactions, M&A and his licensing experience covers protein-based agents and conventional small molecules across multiple therapeutic areas.
Terry holds a BSc (Hons) in Biochemistry and a Ph.D. in Chemistry from the University of Manchester, UK.
Bill Rastetter, Chairman, Illumina; Chairman, Neurocrine Biosciences; Chairman, Fate Therapeutics; Chairman, Receptos, Inc.
Bill was a Partner at Venrock from 2006 to early 2013 and focused on making and growing investments in biotechnology. He serves as chairman for each of four Venrock portfolio companies: Illumina (ILMN, NASDAQ); Neurocrine Biosciences (NBIX, NASDAQ); Receptos (private) and Fate Therapeutics (private). Bill retired at the end of 2005 from Biogen Idec where he was most recently executive chairman. He joined Idec Pharmaceuticals at its founding in 1986 and grew it to a multi-billion-dollar market valuation company, while serving as chairman and CEO. While at Idec, Bill was a co-inventor of Rituxan® that became the first monoclonal antibody approved by the U.S. FDA for cancer; it went on to become one of the world's best selling cancer therapies. Prior to Idec, he was Director of Corporate Ventures at Genentech and also served in a scientific capacity at Genentech. Adding to his corporate background, Bill held various faculty positions at MIT, won the award for "Excellence in the Teaching of Chemistry" at Harvard, and is an Alfred P. Sloan Fellow. Bill is the author of numerous scientific papers and patent applications in the fields of organic and bio-organic chemistry, protein and enzyme engineering, and biotechnology.
John C. Reed, MD, Ph.D., Professor and Donald Bren Chief Executive Chair, Former Chief Executive Officer, Sanford-Burnham Medical Research Institute
Dr. John C. Reed served as Chief Executive Officer at Sanford-Burnham Medical Research Institute, 2002-2013. Sanford-Burnham is a leading biomedical research institute, with over 1,200 employees and operations in San Diego and Orlando, Florida. Under Dr. Reed's leadership, Sanford-Burnham has become one of America's fastest growing biomedical research institutes, achieving impressive revenue growth and attaining the #1 ranking among all organizations worldwide for scientific impact (citations per publication) in the fields of biology and biochemistry for the decade 1999-2009. In 2009, Sanford-Burnham achieved the nation's top ranking among all non-profit life-science organizations for capital efficiency of intellectual property generation (patents issued per dollars spent).
Dr. Reed's research contributions encompass a broad range of therapeutic areas, including oncology, autoimmunity/inflammation, infectious diseases, diabetes, and others. He is a pioneer in delineating the fundamental mechanisms that regulate programmed cell death ("apoptosis"), a process by which cells in the body commit suicide through activation of a genetically controlled program. Much of his work has revealed how defects in programmed cell death contribute to diseases, resulting in novel strategies for therapeutic intervention. Dr. Reed is author of over 800 peer-reviewed scientific articles and over 50 book chapters. He was recognized by the Institute for Scientific Information as the world's most cited scientist in all areas of scientific inquiry from 1997-1999, and was recognized as one of the top 10 "Doctors of the Decade" for publication citations covering the decade 1995-2005, receiving more citations world wide than any other scientist in the field of "cell biology" and in the field of "general biomedicine." Dr. Reed serves or has served on the editorial boards of numerous scientific journals, and as an advisor to NIH, American Cancer Society (ACS), American Association for Cancer Research (AACR), and other biomedical research organizations. He is the recipient of numerous awards for his research accomplishments, and has been awarded more than 100 research grants by a variety of government and non-government funding agencies.
Dr. Reed is a seasoned entrepreneur, serving as scientific founder/co-founder for five biotechnology companies. Dr. Reed's inventions have resulted in over 100 issued Patents, and have spawned numerous drug-discovery programs, including novel therapeutics currently in human clinical trials. He serves or has served as an advisor and consultant to numerous biotechnology and pharmaceutical companies, and on the Board of Directors of several public biopharmaceutical companies.
Tony Rosenberg, Head of Global BD & Licensing, Novartis
Tony Rosenberg is Head Partnering & Emerging Businesses (PEB) and a member of the Pharma Executive Committee.
He joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basle, initially in international product management (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit. In 2005 he was appointed Global Head Business Development & Licensing and has managed over 30 major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas. In 2010 he was given additional responsibility for leadership of the Mo-lecular Diagnostics group.
He is a member of the Board of Directors of the Novartis Venture Option Fund.
Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.
Michael Ross, Managing Partner, SV Life Sciences
Dr. Michael Ross joined SVLS as a Venture Partner in 2001, became a Managing Partner in 2002 and is based in San Francisco. Michael serves on the boards of Adimab, Arsanis Link Medicine, NKT Therapeutics, Rempex and Sutro Biopharmaceuticals. Michael also serves on the Thayer School of Engineering (Dartmouth College). He has also served on the boards of Aderis Pharmaceuticals, Alinea, Archemix, Arris Pharmaceutical, Carta Proteomics, CyThera, Glycofi, Epimmune, Genencor, Ikano, Itero Biopharmaceuticals, MetaXen, Mpex, Rinat and Xenova.
Michael was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha -Roche), Protropin® (hGH), Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. Michael then started Genentech's protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Michael was the Founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Novocell). Michael was also Managing Partner in Didyma, LLC, a biotechnology management consulting firm.
Michael received his AB from Dartmouth College, his PhD in Chemistry at Caltech, and completed a Post Doctorate in Molecular Biology at Harvard.
Jim Schaeffer, Executive Director of Licensing & External Research, Merck Research Labs
Dr. Jim Schaeffer joined Merck Research Laboratories (MRL) in 1986. During his first 16 years at MRL, he directed research groups focusing primarily on neuroendocrine-related projects. Jim joined the Department of External Scientific Affairs in 2003 with primary responsibility for all neuroscience licensing opportunities and during the next 18 months, he was directly involved in the signing of four major agreements. Jim moved to San Diego in 2004 to assume the role of Merck's "Science Scout" on the West Coast, with the responsibility to identify new opportunities across all therapeutic areas at all stages of development including enabling technologies. During the past eight years, Jim has been directly involved in the execution of 14 major agreements with West Coast based organizations including recent agreements with AmbrX, Marcadia, BioAtla, the University of California in San Francisco and the University of Texas-Southwestern. Jim has also been directly involved in the establishment of a Merck-funded research institute (The California Institute for Biomedical Research- Calibr) in La Jolla, California. Calibr will focus on the advancement of early stage innovative research through animal proof of concept.
Dr. Schaeffer received his PhD at Baylor College of Medicine and was a post-doctoral fellow in the laboratory of Dr Julius Axelrod at the National Institute of Mental Health. He is the author of more than 110 articles in peer reviewed journals.
Susan Schaeffer, Editor, BioCentury, The Bernstein Report on BioBusiness
Susan serves as Editor of BioCentury, the Bernstein Report on BioBusiness. She was previously Senior Editor in charge of Product Discovery & Development coverage from 2010 through 2012. She was Managing Editor of BioCentury, the Bernstein Report on BioBusiness, and BioCentury Extra from 2004 through 2010. She joined BioCentury in 2003 after 10 years an editor in the consumer packaged goods sector, including work with international strategy consultants Kurt Salmon Associates.
Jamie Topper, General Partner, Frazier Healthcare
Dr. Topper joined Frazier Healthcare in 2003 as a Venture Partner and became a General Partner in 2005. Dr. Topper is a member of the firm's Biopharma Venture team. Since joining Frazier Healthcare, Dr. Topper has led multiple Biopharma Venture investments including Calistoga Pharmaceuticals that was acquired by Gilead in April 2011 for total consideration of up to $600 million, Alnara Pharmaceuticals that was acquired by Eli Lilly for total consideration of up to $390 million, and Cotherix (Nasdaq CTRX) that was acquired by Actelion for $420 million and a successful PIPE investment in Threshold Pharmaceuticals, Inc. (THLD). Dr. Topper currently serves on the boards of Amicus Therapeutics (Nasdaq FOLD), Atterocor, Portola Pharmaceuticals, Incline Therapeutics, Anaptys Biosciences, Allena Pharmaceuticals and Alcresta Inc. and Rempex Pharmaceuticals. In 2011 Dr. Topper was named to the Forbes Midas list representing the top 100 venture capitalists.
Prior to joining Frazier Healthcare, he served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Prior to the merger of COR and Millennium, Dr. Topper served as the Vice President of Biology at COR and was responsible for managing all of its research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR, where he functioned as a clinician, instructor and basic investigator.
Dr. Topper received his M.D. and Ph.D. (in Biophysics) from Stanford University School of Medicine in 1991 under the auspices of the Medical Scientist Training Program. He completed his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women's Hospital in Boston and is board certified in both disciplines. After completing a research fellowship in the Vascular Research Division in the department of Pathology at the Brigham and Women's hospital, he joined the faculty of Harvard Medical School from 1997 to 1998, and subsequently Stanford University as an Assistant Professor of Medicine (Cardiovascular) in July 1998. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. He continues to hold an appointment as a Clinical Assistant Professor of Medicine at Stanford University and as a Cardiology Consultant to the Palo Alto Veterans Administration Hospital.
Gonul Velicelebi, Founder, President & CEO, CalciMedica
Dr. Velicelebi has more than 25 years of research and management experience in biotechnology. She founded CalciMedica in 2006 based on the discovery of STIM1 and CRAC channel modulators that her group conducted while at TorreyPines Therapeutics. Before founding CalciMedica, Dr. Velicelebi was Vice President of Research and Drug Discovery at TorreyPines Therapeutics since its inception in 2000, and played a key role in its maturation from a start-up to a public company. Prior to TorreyPines Therapeutics, Dr. Velicelebi was Vice President of Research at MitoKor and Director of Cell Biology at SIBIA Neurosciences. Dr. Velicelebi has published extensively in peer-reviewed journals and is an inventor on numerous patents. In 1998, she received the prestigious Science Career Achievement Award in Health Sciences given by the Scientific and Technical Research Council of the Turkish Republic (TUBITAK). Dr. Velicelebi received her BA summa cum laude in chemistry at Randolph-Macon Woman's College, her PhD in biophysical chemistry from Yale University, and completed her postdoctoral fellowship in biochemistry and molecular biology at Harvard University.
Mark Wiggins, SVP, Business Development, Elcelyx
Mr. Wiggins joined Elcelyx Therapeutics in July 2012 as Sr. VP Business Development. Formerly he served as the Chief Business Officer of Mpex Pharmaceuticals overseeing strategic business operations of the company and led the sale of Mpex to Aptalis in 2011. Prior to Mpex, Mr. Wiggins served as Executive Vice President, Corporate and Business Development of Biogen Idec, Inc. for five years. In this position, he was responsible for worldwide partnering, licensing and corporate acquisitions. During his time in this role Biogen-Idec completed approximately 20 significant transactions including multiple global late-stage product collaborations and the purchase of three private companies. Prior to Biogen's merger with Idec Pharmaceuticals in 2003, Mr. Wiggins was the Vice President of Marketing and Business Development at Idec for six years, serving on the senior management committee overseeing the collaboration with Genentech on Rituxan® spanning eleven years. Mr. Wiggins worked for several premier pharmaceutical companies in the commercial area for the first fifteen years of his career including J&J and Pfizer. Mr.Wiggins has served as a member the Zogenix board of directors since May 2011.
Mr.Wiggins received his B.S. degree in Finance from Syracuse University and an M.B.A. from the University of Arizona.
Rob Wills, Vice President, Alliance Management, Johnson & Johnson
Dr Wills is Vice President, Alliance Management, Janssen Pharmaceutical Companies of Johnson & Johnson. He is responsible for managing strategic alliances for the Pharmaceutical Group worldwide. This includes the relationships for Velcade, Xarelto, Incivo, Nucynta, Yondelis and others. As head of Alliance Management, he oversees a small group of professionals who play an active role in the negotiations of alliances (structure, governance, dispute resolution, communication), in leading the integration post-signing and in managing the overall alliances.
Prior to moving into this role in late 2001, Dr Wills spent 22 years in pharmaceutical drug development including, 12 of which have been at Johnson & Johnson. In his previous role as Sr Vice President Global Development, he was responsible for the R&D pipeline and a member of the R&D Board of Directors. In addition he served on several of the commercial Operating Company Boards and key pharmaceutical group decision-making committees. Dr Wills began his career at Hoffmann-LaRoche where he spent 10 years in several roles of scientific responsibility.
Much of Dr Wills' accomplishments are related to his R&D career, which included the successful development of over 30 NDA's, PLA's, MAA's in multiple therapeutic areas. He has authored over 40 peer reviewed research articles, 5 book chapters, and 50 professional presentations or abstracts in the area of pharmacokinetics.
Dr Wills holds a B.S. in Biochemistry and an M.S. in Pharmaceutics from the University of Wisconsin and a Ph.D. in Pharmaceutics from the University of Texas.
Kleanthis Xanthopoulos, President and CEO, Regulus Therapeutics
Kleanthis G. Xanthopoulos, Ph.D. is the President & Chief Executive Officer of Regulus Therapeutics Inc. joining Regulus around its formation in 2007. Prior to that, he was a managing director of Enterprise Partners Venture Capital. Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals from its inception in 2000 to 2006, and remained a Director until its acquitision by Roche in 2011. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals) from 1997 to 2000. Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is a member of the board of directors of the Biotechnology Industry Organization (BIO), Sente Inc., Apricus Bioscience, Inc. and a member of the executive board of BIOCOM, and Southern California's life science industry association.
Barbara Yanni, Vice President and Chief Licensing Officer, Merck
Barbara Yanni is Vice President and Chief Licensing Officer of Merck & Co., Inc. She leads the Corporate Licensing group which is responsible for negotiating agreements to acquire compounds, programs and new technologies to complement Merck's research programs and pipeline. Barbara works closely with her scientific and marketing colleagues at Merck to ensure that the company has access to discoveries that will enhance Merck's ability to bring medicines to patients. Barbara and her team have played a major role in shaping a licensing strategy focused on building strong relationships with partners and potential partners. Merck's rapid, straightforward and clear dealmaking process has made the company an industry leader in the licensing arena. The result has been a significant increase in Merck's external relationships in recent years. In the past five years, Merck has executed approximately 250 significant licensing transactions in all stages, from technologies and early research collaborations to Phase III development candidates.
Before joining Corporate Licensing, Barbara was Executive Director of Corporate Development at Merck where she negotiated acquisitions, divestitures and other business arrangements. Barbara has also worked in other positions in Merck's Finance area including Financial Evaluation and Analysis, Treasury and Tax. She joined Merck in 1985 as Domestic Tax Counsel after working as a tax lawyer for several years at Bristol-Myers and in private practice. Barbara graduated with an A.B. from Wellesley College and a J.D. from Stanford Law School. She also holds a Masters of Law in Taxation from New York University.